Sugi Predict

Sugi Predict / Targets / GUCY1B2

GUCY1B2

Guanylate cyclase soluble subunit beta-2 (GCS · O75343 · GUCY1B2 on Sugi Atlas →

14,027 patent compounds predicted against GUCY1B2, 7,838 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3437351 SCHEMBL3437351 1.00 20/20
SCHEMBL3439299 SCHEMBL3439299 1.00 20/20
SCHEMBL3436905 SCHEMBL3436905 0.87 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL253278) 0.85 20/20
SCHEMBL3436772 SCHEMBL3436772 0.84 20/20
SCHEMBL3437332 SCHEMBL3437332 0.83 20/20
SCHEMBL3436902 SCHEMBL3436902 0.82 20/20
SCHEMBL3436748 SCHEMBL3436748 0.81 20/20
SCHEMBL3436958 SCHEMBL3436958 0.81 20/20
SCHEMBL3437524 SCHEMBL3437524 0.81 20/20
SCHEMBL3437258 SCHEMBL3437258 0.80 20/20
SCHEMBL3437391 SCHEMBL3437391 0.80 20/20
SCHEMBL250991 SCHEMBL250991 0.79 20/20
SCHEMBL3437270 SCHEMBL3437270 0.79 20/20
SCHEMBL3436741 SCHEMBL3436741 0.78 20/20
SCHEMBL3436918 SCHEMBL3436918 0.78 20/20
SCHEMBL3439338 SCHEMBL3439338 0.78 20/20
SCHEMBL252290 SCHEMBL252290 0.78 20/20
SCHEMBL3439239 SCHEMBL3439239 0.77 20/20
SCHEMBL3436743 SCHEMBL3436743 0.77 20/20

Clinical trials — most relevant to GUCY1B2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation PHASE4COMPLETED
Vericiguat and Reverse Remodeling Indices in Heart Failure PHASE4RECRUITING
Impact of Vericiguat on Hemodynamics of Heart Failure PHASE4ACTIVE_NOT_RECRUITING
Bosentan in Treatment of Pulmonary Arterial Hypertension PHASE4COMPLETED
Methylene Blue and Microcirculation in Septic Shock PHASE3UNKNOWN
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE PHASE2UNKNOWN
Dietary Nitrate and Nitrite to Increase Nitric Oxide in Patients With Coronary Artery Disease PHASE2COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD PHASE2RECRUITING
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers PHASE2COMPLETED
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction PHASE2COMPLETED
Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH) PHASE2NOT_YET_RECRUITING
The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension PHASE2COMPLETED
Vascular Effects of Endothelium-Derived Versus Hemoglobin-Transported Nitric Oxide in Healthy Subjects PHASE1COMPLETED
: Vascular Function in Health and Disease PHASE1RECRUITING
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction PHASE1COMPLETED
Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL EARLY_PHASE1UNKNOWN
The Effect of Polymorphism of the GUCY1A3 rs7692387 Gene on Cardiovascular Events After Coronary Artery Bypass Grafting. nanUNKNOWN
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Forced Oscillometry in Infants With Bronchopulmonary Dysplasia nanRECRUITING
Screening for Alpha Thalassemia in Healthy Volunteers nanACTIVE_NOT_RECRUITING
Molecular & Clinical Evaluation of Low HDL Syndromes nanCOMPLETED
Effect of Sodium Nitroprusside on Cerebral Blood Flow nanCOMPLETED
Medtronic Genetic Arrhythmia Markers for Early Detection (GAME Study) nanCOMPLETED
Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GUCY1B2 binder may also engage these)

ProteinNameSimilarity
P22717 — 1.000 P22717 →
Q6DNF3 — 1.000 Q6DNF3 →
Q86C56 — 0.999 Q86C56 →
O02298 — 0.998 O02298 →
P92006 — 0.994 P92006 →
B4LX81 — 0.992 B4LX81 →
P23897 — 0.991 P23897 →
Q6DNF7 — 0.990 Q6DNF7 →
Q9EQW7 — 0.990 Q9EQW7 →
P97311 — 0.990 P97311 →
D4A2Z8 — 0.989 D4A2Z8 →
Q8IUF1 — 0.989 Q8IUF1 →
Q9TYU5 — 0.989 Q9TYU5 →
Q7Q0Q1 — 0.989 Q7Q0Q1 →
A8WPG9 — 0.989 A8WPG9 →
Q23681 — 0.989 Q23681 →
Q5R864 — 0.989 Q5R864 →
Q07093 — 0.989 Q07093 →
Q7JQ32 — 0.989 Q7JQ32 →
DGKG Diacylglycerol kinase gamma 0.989 landscape →
Q296Q5 — 0.989 Q296Q5 →
Q09435 — 0.988 Q09435 →
DGKA Diacylglycerol kinase alpha 0.988 landscape →
P26769 — 0.988 P26769 →
A3QM97 — 0.988 A3QM97 →
P20192 — 0.988 P20192 →
Q9ERL9 — 0.988 Q9ERL9 →
P91550 — 0.988 P91550 →
Q5FWY4 — 0.988 Q5FWY4 →
N1NVB7 — 0.988 N1NVB7 →